NCT02188537 - Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2014

Primary Completion Date

July 26, 2016

Study Completion Date

April 17, 2018

Conditions

Myeloma

Interventions

DRUG

Nelfinavir

Nelfinavir 2x 2500 mg p.o. days 1 - 14

DRUG

bortezomib

Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11

DRUG

Dexamethasone

Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12

Trial Locations (12)

1708

Hopital Fribourgeois, Fribourg

3010

Inselspital Bern, Bern

3600

SpitalSTS AG Simmental-Thun-Saanenland, Thun

5404

Kantonsspital Baden, Baden

6500

Istituto Oncologico Svizzera Italiana IOSI, Bellinzona

8091

UniversitätsSpital Zürich, Zurich

CH-5001

Kantonsspital Aarau, Aarau

CH-4031

Universitaetsspital-Basel, Basel

CH-7000

Kantonsspital Graubuenden, Chur

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER